OpGen, Inc. (NASDAQ: OPGN) is a precision medicine company specializing in molecular diagnostics and digital solutions for infectious disease management. Leveraging next-generation sequencing, bioinformatics and molecular assay technologies, OpGen develops tools designed to detect microbial pathogens and antimicrobial resistance markers rapidly and accurately. The company’s mission is to support clinicians and laboratories in making timely, informed treatment decisions that help curb the spread of drug-resistant infections.
Among OpGen’s key offerings is the Acuitas® AMR Gene Panel, a suite of molecular assays that identify genetic determinants of antibiotic resistance directly from positive blood cultures. These tests are designed to integrate with routine laboratory workflows and compatible instrument platforms, enabling hospitals, reference labs and public health agencies to accelerate pathogen identification and guide targeted antibiotic therapy. OpGen also provides digital reporting and analytics through its informatics platform, which aggregates molecular results with clinical metadata to support antimicrobial stewardship programs.
Headquartered in Gaithersburg, Maryland, with a CLIA-certified laboratory in Baltimore and a major subsidiary in Germany, OpGen serves customers across North America, Europe, Asia-Pacific, Latin America and the Middle East. The company’s global distribution network and strategic partnerships help facilitate adoption of its molecular tests and analytics solutions in diverse healthcare settings.
OpGen is led by President and Chief Executive Officer Evan Jones, who joined the company in 2018 and brings extensive experience in diagnostics and precision medicine. Under his leadership, OpGen has expanded its product portfolio, strengthened its commercial infrastructure and pursued collaborative agreements to broaden access to its infectious disease diagnostics worldwide.
AI Generated. May Contain Errors.
